Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches

Item

http://www.wikidata.org/entity/Q39646028

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches

@en

Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches.

@nl

type

Item

label

Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches

@en

Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches.

@nl

prefLabel

Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches

@en

Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches.

@nl

P1476

Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches

@en

P2093

Andra Balanescu

http://www.w3.org/2001/XMLSchema#string

Carolina Negrei

http://www.w3.org/2001/XMLSchema#string

Daniela Baconi

http://www.w3.org/2001/XMLSchema#string

Mihai Bojinca

http://www.w3.org/2001/XMLSchema#string

Miriana Stan

http://www.w3.org/2001/XMLSchema#string

Violeta Bojinca

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Cytokine pathways and joint inflammation in rheumatoid arthritis.

Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

P304

1177-1183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2016.3045

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Demetrios Spandidos

Aristidis Tsatsakis

P577

2016-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292946343

http://www.w3.org/2001/XMLSchema#string

P698

27073419

http://www.w3.org/2001/XMLSchema#string

P932

4812232

http://www.w3.org/2001/XMLSchema#string